BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Venture Capital in Life Sciences\; A case study with Novartis Vent
 ure Fund
DTSTART:20180919T103000
DTEND:20180919T123000
DTSTAMP:20260407T093420Z
UID:680406fcabc507058a10143961da566195e4f128992c44339fe46ac5
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr Beat Steffen\n\nCatalyze4Life (https://catalyze4life.epfl.c
 h/) is happy to announce the following Life Sciences Innovation Workshop:\
 n \nTitle: “Venture Capital in Life Sciences\; A case study with Novart
 is Venture Fund”\n \nSpeaker: Dr Beat Steffen- Novartis Venture Fund\; 
 Principal\n \nPlace: AI 1153 https://plan.epfl.ch/?room=AI1153 \nDate: 
 Wednesday\, 19.09.2018\nTime: 10:30-12:30\n\nBackground: Catalyze4Life wor
 ks to increase the applicability value of innovative projects\, to help br
 idging the gap between research and industrial development. Thus\, catalyz
 ing innovative life sciences discoveries for society.\nWhen the value of a
  project is determined as based on a careful diligence process\, an approp
 riate path to technology transfer may be determined. The creation of a sta
 rtup may be\, then\, privileged.\n\nThrough this workshop\, Beat/Novartis 
 Venture Fund\, wishes to help\, interested in applicable life sciences res
 earch\, scientists understanding how life sciences investment experts calc
 ulate\, or develop\, the value of a project\, through identifying or struc
 turing specific project elements.\n\nThis workshop shall be interactive. P
 reparation material shall be distributed to participants before the event.
 \n\nThe Workshop shall be limited to 30 participants (1st come 1st served)
 . Participants with applicable projects are encouraged.\nYou can participa
 te at: https://epfl.doodle.com/poll/5t4b84sanrg25sds\n\nLooking forward t
 o your participation\,\n \nBart Deplancke & Kostas Kaloulis\n\nBeat's Bio
 graphy:\nDr. Beat Steffen is a Principal in Basel\, Switzerland. Prior to 
 joining Novartis Venture Fund\, he worked at Novartis Pharmaceuticals in c
 ommercial roles in the US and in Switzerland launching several products ma
 inly in the cardiovascular area. Beat joined Novartis from Wellington Part
 ners Venture Capital where he worked with biotech and medical device start
 up companies. Prior to that\, he was at McKinsey & Company in Zurich worki
 ng with clients in the pharmaceutical industry. Beat is a Swiss-trained ph
 ysician having focused in cardiovascular surgery and intensive care. He gr
 aduated from the University of Zurich Medical School and qualified as a Me
 dical Doctor in Basel. Beat holds an MBA with distinction from INSEAD. Bea
 t serves on the boards of Aelin Therapeutics\, and the University of Zuric
 h Life Sciences Fund.\n\nNovartis Venture Fund: \nNovartis Venture Funds 
 is a private equity and venture capital arm of Novartis AG specializing in
  investments in early startup companies\, seed\, growth capital\, Series A
 \, and later stage investment. The firm is stage agnostic and makes early\
 , mid and late venture investments. It seeks to invest in\nbiotech/biophar
 ma\, medical devices and diagnostics\, and life sciences companies with a 
 focus on new novel therapeutics and platforms\; medical devices and implan
 ts\; diagnostics and biomarkers\; and drug delivery and biopolymers. www.n
 vfund.com\n\nKey words: Life Sciences Innovation\, Startups\, Technology T
 ransfer\, Valuation\, Business Case\, Investment Case\, New therapeutics 
 & platforms\, Medical devices/implants\, Diagnostics/biomarkers\, Drug del
 ivery/biopolymers\n\n\n 
LOCATION:AI 1153 https://plan.epfl.ch/?room==AI%201153
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR